Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088890 · ClinicalTrials.gov registry record · Phase 1
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
A Phase 1 study of B-Cell Non-Hodgkin Lymphoma and DLBCL, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04088890 is a Phase 1 study of B-Cell Non-Hodgkin Lymphoma and DLBCL that has completed, run by Stanford University. The registered enrollment target is 52 participants, below the 128-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04088890, a Phase 1 study of B-Cell Non-Hodgkin Lymphoma and DLBCL, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG CD22 CAR
Study Locations (1)
California
- Stanford Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2025-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088890
The ClinicalTrials.gov registry entry for NCT04088890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (59% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04088890 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04088890 about?
NCT04088890 is a clinical study titled "Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies". The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from adults with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
What is the current status of trial NCT04088890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-09-12. Estimated completion is 2025-03-07.
What conditions does trial NCT04088890 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, DLBCL, B-ALL, Follicular Lymphoma Grade 3B.
What interventions are being tested in trial NCT04088890?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CD22 CAR (DRUG).
Who is sponsoring clinical trial NCT04088890?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04088890 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.